Tecentriq Hybreza (Atezolizumab and Hyaluronidase-Tqjs) for Melanoma

Overview
Tecentriq Hybreza is approved by the U.S. Food and Drug Administration (FDA) in combination with cobimetinib and vemurafenib for the treatment of adults with BRAF V600 mutation-positive unresectable or metastatic melanoma. A person must have their BRAF mutation status confirmed by an FDA-approved test to be eligible for this treatment. Tecentriq Hybreza is also known by its drug name, atezolizumab and hyaluronidase-tqjs.

Tecentriq Hybreza is an immunotherapy that blocks a protein called PD-L1, which allows the immune system to better detect and attack cancer cells. Hyaluronidase, an enzyme included in the formulation, enhances the absorption of the drug when injected subcutaneously (under the skin).

How do I take it?
Prescribing information states that Tecentriq Hybreza is administered subcutaneously (under the skin) into the thigh by a health care professional. The recommended dose is injected over approximately seven minutes every three weeks. Following a 28-day cycle of cobimetinib and vemurafenib, Tecentriq Hybreza is typically given every three weeks along with cobimetinib taken orally (21 days on, seven days off) and vemurafenib taken orally twice daily. It should be taken exactly as prescribed by a health care provider.

Side effects
Common side effects of Tecentriq Hybreza include rash, musculoskeletal pain (pain in muscles and bones), fatigue, hepatotoxicity (liver damage), pyrexia (fever), nausea, pruritus (itchy skin), edema (swelling), stomatitis (inflammation of the mouth), hypothyroidism (underactive thyroid), and photosensitivity reactions (increased sensitivity to sunlight).

Rare but serious side effects may include immune-mediated adverse reactions affecting organs and tissues, such as pneumonitis (lung inflammation), colitis (inflammation of the colon), hepatitis (liver inflammation), endocrinopathies (hormonal disorders), and nephritis (kidney inflammation). Fatal and other serious complications may also occur in individuals who receive hematopoietic stem cell transplantation before or after being treated with a PD-1/PD-L1 blocking antibody.  

For more information about this treatment, visit:

Tecentriq Hybrezatm (Atezolizumab and Hyaluronidase-Tqjs) Injection, for Subcutaneous Use — U.S. Food & Drug Administration

Tecentriq Hybreza — Drugs.com